



Published in final edited form as:

Science. 2013 October 11; 342(6155): 253–257. doi:10.1126/science.1242088.

An erythroid enhancer of *BCL11A* subject to genetic variation determines fetal hemoglobin level

Daniel E. Bauer^{1,2,4}, Sophia C. Kamran^{4,5}, Samuel Lessard⁶, Jian Xu^{1,4}, Yuko Fujiwara¹, Carrie Lin¹, Zhen Shao¹, Matthew C. Canver⁴, Elenoe C. Smith¹, Luca Pinello³, Peter J. Sabo⁷, Jeff Vierstra⁷, Richard A. Voit⁸, Guo-Cheng Yuan^{3,9}, Matthew H. Porteus⁸, John A. Stamatoyannopoulos⁷, Guillaume Lettre⁶, and Stuart H. Orkin^{1,2,4,5,*}

¹Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, 02115

²Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115

³Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02115

⁴Harvard Medical School, Boston, MA, 02115

⁵Howard Hughes Medical Institute, Boston, MA, 02115

⁶Montreal Heart Institute and Université Montréal, Montreal, Quebec, H1T 1C8, Canada

⁷Departments of Genome Sciences and Medicine, University of Washington, Seattle, WA, 98195

⁸Department of Pediatrics, Stanford University, Palo Alto, CA, 94304

⁹Harvard School of Public Health, Boston, MA, 02115

Abstract

Genome-wide association studies (GWAS) have ascertained numerous trait-associated common genetic variants, frequently localized to regulatory DNA. We find that common genetic variation at *BCL11A* associated with fetal hemoglobin (HbF) level lies in noncoding sequences decorated by an erythroid enhancer chromatin signature. Fine-mapping uncovers a motif-disrupting common variant associated with reduced transcription factor binding, modestly diminished *BCL11A* expression and elevated HbF. The surrounding sequences function *in vivo* as a developmental stage-specific lineage-restricted enhancer. Genome engineering reveals the enhancer is required in erythroid but not B-lymphoid cells for *BCL11A* expression. These findings illustrate how GWAS may expose functional variants of modest impact within causal elements essential for appropriate gene expression. We propose the GWAS-marked *BCL11A* enhancer represents an attractive target for therapeutic genome engineering for the β -hemoglobinopathies.

*Correspondence: Stuart_Orkin@dfci.harvard.edu.

Supplementary Materials

www.sciencemag.org

Materials and Methods

Supplementary Text

Figs. S1–S9

Tables S1–S6

References (39–55)

GWAS have identified numerous common single nucleotide polymorphisms (SNPs) associated with human traits and diseases. However advancing from genetic association to causal biologic process has been challenging (1). Recent genome-scale chromatin mapping studies have highlighted the enrichment of GWAS variants in regulatory DNA elements, suggesting many causal variants may affect gene regulation (2–6). GWAS of HbF level have identified trait-associated variants at *BCL11A* (7–12) (see supplementary online text). The transcriptional repressor *BCL11A* has been validated as a direct regulator of HbF level (13–18). Although constitutive *BCL11A* deficiency results in embryonic lethality and impaired lymphocyte development (19, 20), erythroid-specific deficiency of *BCL11A* counteracts developmental silencing of embryonic and fetal globin genes and rescues the hematologic and pathologic features of sickle cell disease (SCD) in mouse models (17).

To further understand how common genetic variation impacts *BCL11A*, HbF level and β -globin disorder severity, we compared the distribution of the HbF-associated SNPs at *BCL11A* with DNase I sensitivity, an indicator of chromatin state suggestive of regulatory potential. In primary human erythroblasts, three peaks of DNase I hypersensitivity were observed in intron-2, adjacent to and overlying the HbF-associated variants (Fig. 1A). We term these DNase I hypersensitive sites (DHSs) +62, +58 and +55 based on distance in kb from the transcription start site (TSS) of *BCL11A*. Brain and B-lymphocytes, two tissues that express high levels, and T-lymphocytes, which do not express *BCL11A*, showed unique patterns of DNase I sensitivity at the *BCL11A* locus, with a paucity of hypersensitivity overlying the trait-associated SNPs (Figs. 1A and S1).

ChIP-seq demonstrated histone modifications with an enhancer signature overlying the trait-associated SNPs at *BCL11A* intron-2, including the presence of H3K4me1 and H3K27ac, and absence of H3K4me3 and H3K27me3 marks (Figs. 1A and S1). The major erythroid transcription factors (TFs) GATA1 and TAL1 also occupy this enhancer region. ChIP-qPCR confirmed three discrete peaks of GATA1 and TAL1 binding within *BCL11A* intron-2, each falling within an erythroid DHS (Fig. 1B). A common feature of distal regulatory elements is long-range interaction with cognate promoters. We evaluated the interactions between the *BCL11A* promoter and fragments across 250 kb of the *BCL11A* locus using a chromosome conformation capture assay. The greatest promoter interaction was observed within the region of intron-2 containing the trait-associated SNPs (Fig. 1C).

We hypothesized that the causal trait-associated SNPs could function by modulating critical cis-regulatory elements. Therefore we performed extensive genotyping of SNPs within the three erythroid DHSs +62, +58 and +55 in 1,263 DNA samples from the Cooperative Study of SCD (CSSCD) (21). 1,178 individuals and 38 SNPs were used for association testing (Fig. S2A). Analysis of common variants (MAF > 1%) revealed that rs1427407 in DHS +62 had the strongest association to HbF level ($P = 7.23 \times 10^{-50}$; Figs. 2A and S2B, also see supplementary online text). We identified associations to HbF level within the three DHSs that remained following conditioning on rs1427407 (Figs. 2A and S2B), consistent with the hypothesis that multiple functional SNPs within the composite enhancer act combinatorially to influence *BCL11A* regulation. The most significant residual association was for rs7606173 in DHS +55 ($P = 9.66 \times 10^{-11}$).

The SNP rs1427407 falls within a peak of GATA1 and TAL1 binding (Figs. 1A and 1B). The minor T-allele disrupts the G-nucleotide of a sequence element resembling a half E-box/GATA composite motif [CTG(n_g)GATA], a consensus sequence enriched for chromatin bound by GATA1 and TAL1 complexes in erythroid cells (22, 23). We identified five primary erythroblast samples from individuals heterozygous for the major G-allele and minor T-allele at rs1427407 and subjected these samples to ChIP followed by pyrosequencing. As anticipated, we observed an even balance of alleles in the input DNA. However, we detected more frequent binding to the G-allele compared to the T-allele in both the GATA1 and TAL1 immunoprecipitated chromatin samples (Fig. 2B).

As the common synonymous SNP rs7569946 lies within exon-4 of *BCL11A*, it can be used to discriminate expression of alleles. We identified three primary erythroblast samples doubly heterozygous for the rs1427407–rs7606173 haplotype and rs7569946. For each sample, we determined by molecular haplotyping that the major rs7569946 G-allele was in phase with the low-HbF associated rs1427407–rs7606173 G–C haplotype (Table S4) (24, 25). Pyrosequencing revealed that whereas the alleles were balanced in genomic DNA (gDNA), significant imbalance was observed in complementary DNA (cDNA) with 1.7-fold increased expression of the low-HbF linked G-allele of rs7569946 (Fig. 2C, also see supplementary online text).

To understand the context within which these apparent regulatory trait-associated SNPs play their role, we explored the function of the harboring composite element. We cloned a 12.4 kb (+52.0–64.4 kb from TSS) human gDNA fragment containing the three erythroid DHSs to assay enhancer potential in a murine transgenic *lacZ* reporter assay (Fig. S4). Endogenous *BCL11A* shows abundant expression throughout the developing central nervous system with much lower expression observed in the fetal liver (26). In contrast, we observed in the transgenic embryos reporter gene expression largely confined to the fetal liver, the site of definitive erythropoiesis, with weaker expression noted in the central nervous system (Fig. 3A).

A characteristic feature of globin gene and *BCL11A* expression is developmental regulation (see supplementary online text). In stable transgenic *BCL11A* +52.0–64.4 reporter lines at 12.5 dpc, circulating primitive erythrocytes failed to stain for X-gal whereas definitive erythroblasts in fetal liver robustly stained positive (Fig. 3B). Endogenous *BCL11A* was expressed at 10.4-fold higher levels in B-lymphocytes as compared to erythroblasts. *LacZ* expression was restricted to erythroblasts and not observed in B-lymphocytes (Fig. 3C). These results indicate that the GWAS-marked *BCL11A* intron-2 regulatory sequences are sufficient to specify developmentally-restricted, erythroid-specific gene expression.

We aimed to disrupt the enhancer to investigate its requirement for *BCL11A* expression. Since there are no suitable adult-stage human erythroid cell lines, we turned to the mouse erythroleukemia (MEL) cell line. We observed an orthologous enhancer signature at intron-2 of mouse *Bcl11a* indicated by sequence homology, erythroid-specific DNase I hypersensitivity, characteristic histone marks and GATA1/TAL1 occupancy (Fig. S6) (22, 27). Sequence-specific nucleases can produce small chromosomal deletions via NHEJ-mediated repair (28). We engineered TALENs to introduce double-strand breaks to flank the

orthologous 10 kb *Bcl11a* intron-2 sequences carrying the erythroid enhancer chromatin signature (Fig. S7A). Three unique clones were isolated that had undergone biallelic excision of the intronic segment (Figs. S7 and S8, also see supplementary online text). BCL11A transcript was profoundly reduced in the absence of the orthologous erythroid composite enhancer (Fig. 4A). BCL11A protein expression was not detectable in the enhancer-deleted clones (Fig. 4B). In the absence of the BCL11A enhancer, embryonic globin gene derepression was pronounced, with the ratio of embryonic $\epsilon\gamma$ to adult $\beta 1/2$ globin increased by a mean of 364-fold (Fig. S9).

To examine potential lineage-restriction of the requirement for the +50.4–60.4 kb intronic sequences for BCL11A expression, we evaluated their loss in a non-erythroid context. The same strategy of introduction of two pairs of TALENs to obtain clones with NHEJ-mediated deletion was employed in a pre-B lymphocyte cell line. In contrast to the erythroid cells, BCL11A expression was retained in the 50.4–60.4 kb enhancer deleted pre-B cell clones at both the RNA and protein levels (Figs. 4A and 4B). These results indicate the orthologous erythroid enhancer sequences are essential for erythroid gene expression but not required in B-lymphoid cells for integrity of transcription from the *Bcl11a* locus.

The prior identification of BCL11A as a critical repressor of HbF levels has raised new hope for mechanism-based therapeutic approaches to the β -hemoglobinopathies (29). However, the paradox that genetic variation at *BCL11A* is common, well-tolerated and disease-protective despite the critical roles of BCL11A in neurogenesis and lymphopoiesis (19, 20, 30) has remained unresolved. Here we demonstrate that the HbF-associated variants localize to an erythroid enhancer of *BCL11A*. By allele-specific analyses, we show that genetic variation within this enhancer is associated with modest impact on TF binding, BCL11A expression and HbF level. Relatively small effect sizes associated with individual variants may not be surprising given that most single nucleotide substitutions, even within critical motifs, result in only modest loss of enhancer activity (31, 32). In contrast, loss of the *BCL11A* enhancer results in the absence of BCL11A expression in the erythroid lineage. Most trait-associated SNPs identified by GWAS are noncoding and have small effect size (1, 33). The impact of GWAS-identified SNPs on biological processes is often uncertain. Our findings underscore how a modest influence engendered by an individual noncoding variant neither predicts nor precludes a profound contribution of an underlying regulatory element.

Challenges to inhibiting BCL11A for mechanism-based reactivation of HbF include the supposedly “undruggable” nature of transcription factors (34) and its important non-erythroid functions (20, 30). With recent developments in their efficiency and precision, sequence-specific nucleases can be designed to exquisitely target genomic sequences of interest (35–37). We propose the GWAS-identified enhancer of *BCL11A* as a particularly promising therapeutic target for genome engineering in the β -hemoglobinopathies. Disruption of this enhancer would impair BCL11A expression in erythroid precursors with resultant HbF derepression, while sparing BCL11A expression in non-erythroid lineages. Rational intervention might mimic common protective genetic variation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Thanks to A. Woo, A. Cantor, M. Kowalczyk, S. Burns, J. Wright, J. Snow, J. Trowbridge and members of the Orkin laboratory, particularly C. Peng, P. Das, G. Guo, M. Kerényi, and E. Baena, for discussions. C. Guo and F. Alt provided the pre-B cell line, A. He and W. Pu the pWHERE lacZ reporter construct, C. Currie and M. Nguyen technical assistance, D. Bates and T. Kutayav expertise with sequence analysis, R. Sandstrom help with data management, G. Losyev and J. Daley aid with flow cytometry and J. Desimini graphical assistance. L. Yan at EpigenDx (Hopkinton, Massachusetts) conducted the custom pyrosequencing reactions. This work was funded by grants from the Doris Duke Charitable Foundation (#2009089) and Canadian Institute of Health Research (#123382) to G.L.; Amon Carter Foundation, Hyundai Hope on Wheels, NIH, Lucille Packard Foundation to M.H.P.; NIH grants U54HG004594 and U54HG007010 to J.A.S.; and NIH R01HL032259, P01HL032262, and P30DK049216 (Center of Excellence in Molecular Hematology) to S.H.O. D.E.B. is supported by NIDDK Career Development Award K08DK093705. A patent application related to this work was filed by Boston Children's Hospital, and D.E.B., J.X., and S.H.O. are inventors.

References

1. Fugger L, McVean G, Bell JI. *N Engl J Med*. 2012; 367:2370–2371. [PubMed: 23252523]
2. Ernst J, et al. *Nature*. 2011; 473:43–49. [PubMed: 21441907]
3. Paul DS, et al. *PLoS Genet*. 2011; 7:e1002139. [PubMed: 21738486]
4. Maurano MT, et al. *Science*. 2012; 337:1190–1195. [PubMed: 22955828]
5. van der Harst P, et al. *Nature*. 2012; 492:369–375. [PubMed: 23222517]
6. ENCODE Project Consortium et al. *Nature*. 2012; 489:57–74. [PubMed: 22955616]
7. Menzel S, et al. *Nat Genet*. 2007; 39:1197–1199. [PubMed: 17767159]
8. Uda M, et al. *Proc Natl Acad Sci U S A*. 2008; 105:1620–1625. [PubMed: 18245381]
9. Lettre G, et al. *Proc Natl Acad Sci U S A*. 2008; 105:11869–11874. [PubMed: 18667698]
10. Nuinon M, et al. *Hum Genet*. 2010; 127:303–314. [PubMed: 20183929]
11. Solovieff N, et al. *Blood*. 2010; 115:1815–1822. [PubMed: 20018918]
12. Bhatnagar P, et al. *J Hum Genet*. 2011; 56:316–323. [PubMed: 21326311]
13. Sankaran VG, et al. *Science*. 2008; 322:1839–1842. [PubMed: 19056937]
14. Xu J, et al. *Genes Dev*. 2010; 24:783–798. [PubMed: 20395365]
15. Xu J, et al. *Proc Natl Acad Sci U S A*. 2013; 110:6518–6523. [PubMed: 23576758]
16. Sankaran VG, et al. *Nature*. 2009; 460:1093–1097. [PubMed: 19657335]
17. Xu J, et al. *Science*. 2011; 334:993–996. [PubMed: 21998251]
18. Esteghamat F, et al. *Blood*. 2013; 121:2553–2562. [PubMed: 23361909]
19. Liu P, et al. *Nat Immunol*. 2003; 4:525–532. [PubMed: 12717432]
20. Yu Y, et al. *J Exp Med*. 2012; 209:2467–2483. [PubMed: 23230003]
21. Farber MD, Koshy M, Kinney TR. *J Chronic Dis*. 1985; 38:495–505. [PubMed: 4008590]
22. Soler E, et al. *Genes Dev*. 2010; 24:277–289. [PubMed: 20123907]
23. Kassouf MT, et al. *Genome Res*. 2010; 20:1064–1083. [PubMed: 20566737]
24. Turner DJ, Hurler ME. *Nat Protoc*. 2009; 4:1771–1783. [PubMed: 20010928]
25. Tyson J, Armour JA. *BMC Genomics*. 2012; 13:693–2164-13-693. [PubMed: 23231411]
26. Leid M, et al. *Gene Expr Patterns*. 2004; 4:733–739. [PubMed: 15465497]
27. Kowalczyk MS, et al. *Mol Cell*. 2012; 45:447–458. [PubMed: 22264824]
28. Lee HJ, Kim E, Kim JS. *Genome Res*. 2010; 20:81–89. [PubMed: 19952142]
29. Bauer DE, Kamran SC, Orkin SH. *Blood*. 2012; 120:2945–2953. [PubMed: 22904296]
30. John A, et al. *Development*. 2012; 139:1831–1841. [PubMed: 22491945]
31. Patwardhan RP, et al. *Nat Biotechnol*. 2012; 30:265–270. [PubMed: 22371081]

32. Melnikov A, et al. *Nat Biotechnol.* 2012; 30:271–277. [PubMed: 22371084]
33. Frazer KA, Murray SS, Schork NJ, Topol EJ. *Nat Rev Genet.* 2009; 10:241–251. [PubMed: 19293820]
34. Koehler AN. *Curr Opin Chem Biol.* 2010; 14:331–340. [PubMed: 20395165]
35. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. *Nat Rev Genet.* 2010; 11:636–646. [PubMed: 20717154]
36. Joung JK, Sander JD. *Nat Rev Mol Cell Biol.* 2013; 14:49–55. [PubMed: 23169466]
37. van der Oost J. *Science.* 2013; 339:768–770. [PubMed: 23413345]




Fig. 1. Chromatin state and TF occupancy at *BCL11A*

(A) ChIP-seq from human erythroblasts with indicated antibodies. DNase I cleavage density from indicated human tissues. Three erythroid DHSs termed +62, +58 and +55 based on distance in kb from *BCL11A* TSS. *BCL11A* transcription from right to left.

(B) ChIP-qPCR from human erythroblasts at *BCL11A* intron-2. DHSs +62, +58 and +55 boxed. Enrichment at negative (*GAPDH*, *OCT4*) and positive control (β -globin LCR HS3 and α -globin HS-40) loci displayed.

(C) Chromosome conformation capture in human erythroblasts using *BCL11A* promoter as anchor. Error bars indicate s.d.




Fig. 2. Regulatory variants at *BCL11A*

(A) Genotype data obtained in 1,178 individuals from CSSCD for 38 variants within *BCL11A* +62, +58 or +55 DHSs. Most highly significant associations to HbF level among common (MAF > 1%) SNPs ($n = 10$) prior to (rs1427407) or following (rs7606173) conditional analysis on rs1427407. SNP coordinates chromosome 2, build hg19.

(B) Chromatin from erythroblasts of individuals heterozygous for rs1427407, immunoprecipitated by GATA1 or TAL1 and pyrosequenced to quantify the relative abundance of the rs1427407-G allele. Composite half E-box–GATA motif previously identified (23).

(C) gDNA and cDNA from erythroblasts of individuals heterozygous for rs1427407, rs7606173 and rs7569946. Haplotyping demonstrated rs7569946-G, rs1427407-G and rs7606173-C on the same chromosome in each. Pyrosequencing to quantify the relative abundance of the rs7569946-G allele.




Fig. 3. The GWAS-marked *BCL11A* enhancer is sufficient for adult-stage erythroid expression

(A) A 12.4-kb fragment of *BCL11A* intron-2 (+52.0–64.4 kb from TSS) was cloned to a *lacZ* reporter construct. Transient transgenic mouse embryo from 12.5 dpc X-gal stained. Arrowhead indicates liver.

(B) Cell suspensions isolated from peripheral blood (PB) and fetal liver (FL) of stable transgenic embryos at 12.5 dpc X-gal stained.

(C) Sorted erythroblasts and B-lymphocytes from young adult stable transgenic mice subject to X-gal staining or RNA isolation followed by RT-qPCR. Gene expression normalized to GAPDH and expressed relative to T-lymphocytes. Error bars indicate s.d.




Fig. 4. The GWAS-marked *BCL11A* enhancer is necessary for erythroid but dispensable for non-erythroid expression

(A) Three mouse erythroleukemia (MEL) and two pre-B lymphocyte clones with biallelic deletion of the orthologous *Bcl11a* erythroid enhancer (50.4–60.4) subject to RT-qPCR.

(B) Immunoblot of 50.4–60.4 MEL and pre-B lymphocyte clones.